A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer

NCT07672743 · tracked via the Priya Life Science China tracker

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase

Not applicable

Started

2026-06-30

Last updated

2026-06-29

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Radical dose radiotherapy

Radical dose radiotherapy: Radical dose is delivered for the patients. SFRT is recommended for the patients with bulky tumor (such as ≥ 5cm). SFRT is delivered with 12-20Gy (1 fraction) followed by external beam radiation therapy (EBRT) with EQD2≥60Gy.

Study summary

For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the local control of radical dose RT or new RT technique (such as patially fractionated radiation therapy, SFRT) for the locally advanced or recurrent metastatic breast cancer.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * Locally advanced or recurrent metastatic breast cancer, pathologically confirmed; * At least one extracranial measurable lesion suitable for radiotherapy; * Signature of informed consent form. Exclusion Criteria: * Pregnant or lactation women; * Severe concomitant conditions, including persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, and serious arrhythmias et al.

Primary outcome measure(s)

Overall Response Rate (ORR) — 3 months

Trial sites (1)

Facility	City	Region	Status
Cancer Hospital, Chinese Academy of Medical Sciences	Beijing	Beijing Municipality

More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China

Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer Active, not recruiting

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC Enrolling by invitation

Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study Recruiting

Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases Recruiting

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC Recruiting

Other trials for the same condition

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors Recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07672743 on ClinicalTrials.gov ↗ ← All trials in China